Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.

IF 11.4 1区医学 Q1 ONCOLOGY

Journal of Experimental & Clinical Cancer Research Pub Date : 2025-03-05 DOI:10.1186/s13046-025-03318-6

Zelin Li, Shuhan Liu, Deyu Liu, Kangping Yang, Jing Xiong, Ziling Fang

引用次数: 0

Abstract

Background: Immune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse events. Therefore, identifying factors that can predict treatment outcomes, enhance synergy with ICB, and mitigate immune-related adverse events is urgently needed.

Main text: Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues that arise from the tumor periphery. They have been found to be associated with better prognosis and improved clinical outcomes after ICB therapy. TLS may help address the problems associated with ICB. The multiple mechanisms of action between TLS and ICB remain unknown. This paper described potential mechanisms of interaction between the two and explored their potential applications.

查看原文本刊更多论文

三级淋巴结构和免疫检查点阻断的多种机制和应用。

背景：免疫检查点阻断（Immune checkpoint blockade， ICB）抑制肿瘤免疫逃逸，对肿瘤治疗具有重要的促进作用。然而，ICB仅使少数接受治疗的患者受益，并可能导致许多与免疫相关的不良事件。因此，迫切需要确定能够预测治疗结果的因素，增强与ICB的协同作用，并减轻免疫相关不良事件。主要内容：三级淋巴组织（TLS）是肿瘤周围产生的异位淋巴组织。发现它们与ICB治疗后更好的预后和改善的临床结果相关。TLS可以帮助解决与ICB相关的问题。TLS和ICB之间的多种作用机制尚不清楚。本文描述了两者相互作用的潜在机制，并探讨了它们的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental & Clinical Cancer Research 医学-肿瘤学

CiteScore

18.20

自引率

1.80%

发文量

333

审稿时长

1 months

期刊介绍： The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications. We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options. We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us. We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community. By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.